Filter By Industry
Filter By Tag

Newsroom

NAPSRx Press releases

11 - 20 of 357 Press Releases

Jun 05, 2015
The U.S. Food and Drug Administration’s (FDA) meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee has decided to support the approval of the benefit/risk profile of Sprout...

May 29, 2015
The U.S. Food and Drug Administration (FDA) has approved Pfizer’s RAPAMUNE® (sirolimus) making it the first approved therapy to treat lymphangioleiomyomatosis (LAM), a rare disease that affects the lungs, kidneys and the lymphatic system, which tends...

May 28, 2015
Valeant Pharmaceutical’s wholly owned subsidiary, Salix Pharmaceuticals, Inc received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan® 550 mg to treat IBS-D (Irritable Bowel Syndrome with Diarrhea) in adults.

May 21, 2015
Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines.

May 19, 2015
In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.

May 13, 2015
Baxter is ready to expand its oncology segment by acquiring Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A for USD $900 million.

May 08, 2015
The investigational drug venetoclax has been granted Breakthrough Therapy Designation from the U.S.

May 06, 2015
Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...

May 05, 2015
Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.

Apr 30, 2015
On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.


Page: Prev 1 2 3 4 5 Next
NAPSRx RSS Feed